For the Patients

For Patients

At Eisai we strive to prioritise patients and their families through our focus to continually improve the benefits that health care can provide.

Below is a list of our medicines that are currently available in Australia. For further information on any of our products please access the Consumer Medicines Information (CMI) via the links below.

Please always ask your healthcare professional for advice regarding medicines.

Patients

Reporting Side Effects

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Consumer Medicines Information document.

Adverse events may also be reported to Eisai Australia Ltd.
Safety_Australia@eisai.net
tel: +61 (03) 9832 9100

Oncology

  • Lenvima®

    lenvatinib     CMI

  • Halaven®

    eribulin mesilate     CMI

  • Gliadel®

    carmustine     CMI

Neurology

  • Fycompa®

    perampanel     CMI

  • Inovelon®

    rufinamide     CMI

  • Dayvigo®

    lemborexant     CMI
Lenvima®, Halaven®, Gliadel®, Fycompa®, Inovelon®, Dayvigo® are all registered trademarks of the Eisai Group, whose affiliate company in Australia is Eisai Australia Ltd, Level 2, 437 St Kilda Road, Melbourne VIC, 3004.

Reporting Side Effects

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Consumer Medicines Information document.

Adverse events may also be reported to Eisai Australia Ltd.
Safety_Australia@eisai.net
tel: +61 (03) 9832 9100